TRACING THE TRAJECTORY OF INDUSTRY LEADER’S DRUG INNOVATION CAPABILITY: THE AMGEN CORPORATION CASE

Victor Oladapo and Godwin Onyeaso

Review of Business and Finance Studies, 2013, vol. 4, issue 2, 69-77

Abstract: The origin of organizational capabilities remains elusive to strategy managers and scholars. Because of this elusiveness, a scholar has questioned: where [do] capabilities come from [and] what kinds of investment in money, time, and managerial efforts is required in building them [Ethiraj, et al. 2005, Strategic Management Journal, 26, 25-45]. Using the lens of the upper echelon theory, this case provides evidence that Amgen’s President hired stair-scientists who then developed the first drugs that launched Amgen as the global biopharmaceutical industry leader. This way, this case study contributes answers to the questions raised by Ethiraj and colleagues (2005). In sum, this real-world case discussion has practical significance to managers and academics alike.

Keywords: Upper Echelon; Drug Innovation; Capabilities; Network Capabilities (search for similar items in EconPapers)
JEL-codes: M1 M2 (search for similar items in EconPapers)
Date: 2013
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://www.theibfr2.com/RePEc/ibf/rbfstu/rbfs-v4n2-2013/RBFS-V4N2-2013-7.pdf (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:ibf:rbfstu:v:4:y:2013:i:2:p:69-77

Access Statistics for this article

Review of Business and Finance Studies is currently edited by Terrance Jalbert

More articles in Review of Business and Finance Studies from The Institute for Business and Finance Research
Bibliographic data for series maintained by Mercedes Jalbert ( this e-mail address is bad, please contact ).